Chris Ehrlich
Tracked across 1 events · 6 articles · First seen Jun 15, 2026 · Last active Jun 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Chris Ehrlich, CEO of Coeptis Therapeutics Holdings, provided commentary on the encouraging findings from the CERTAIN-T trial, highlighting the observed clinical improvement and the company's plans for dose escalation and further evaluation of CER-1236.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Chris Ehrlich live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard